These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15794863)

  • 1. Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia.
    Dimopoulos MA; Anagnostopoulos A; Zervas C; Kyrtsonis MC; Zomas A; Bourantas C; Anagnostopoulos N; Pangalis G
    Clin Lymphoma; 2005 Mar; 5(4):270-2. PubMed ID: 15794863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression.
    Dimopoulos MA; Alexanian R; Gika D; Anagnostopoulos A; Zervas C; Zomas A; Kyrtsonis MC; Anagnostopoulos N; Pangalis GA; Weber DM
    Leuk Lymphoma; 2004 Oct; 45(10):2057-61. PubMed ID: 15370250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Waldenström's macroglobulinemia with rituximab.
    Dimopoulos MA; Zervas C; Zomas A; Kiamouris C; Viniou NA; Grigoraki V; Karkantaris C; Mitsouli C; Gika D; Christakis J; Anagnostopoulos N
    J Clin Oncol; 2002 May; 20(9):2327-33. PubMed ID: 11981004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia.
    Dimopoulos MA; Zervas C; Zomas A; Hamilos G; Gika D; Efstathiou E; Panayiotidis P; Vervessou E; Anagnostopoulos N; Christakis J
    Clin Lymphoma; 2002 Dec; 3(3):163-6. PubMed ID: 12521393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended rituximab therapy in Waldenström's macroglobulinemia.
    Treon SP; Emmanouilides C; Kimby E; Kelliher A; Preffer F; Branagan AR; Anderson KC; Frankel SR;
    Ann Oncol; 2005 Jan; 16(1):132-8. PubMed ID: 15598950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity.
    Byrd JC; White CA; Link B; Lucas MS; Velasquez WS; Rosenberg J; Grillo-López AJ
    Ann Oncol; 1999 Dec; 10(12):1525-7. PubMed ID: 10643548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy.
    Liberato B; Riethmuller A; Comenzo RL; Lis E; Raizer JJ
    J Neurooncol; 2003 Jun; 63(2):207-11. PubMed ID: 12825826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
    Treon SP; Hansen M; Branagan AR; Verselis S; Emmanouilides C; Kimby E; Frankel SR; Touroutoglou N; Turnbull B; Anderson KC; Maloney DG; Fox EA
    J Clin Oncol; 2005 Jan; 23(3):474-81. PubMed ID: 15659493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
    Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.
    Treon SP; Branagan AR; Hunter Z; Santos D; Tournhilac O; Anderson KC
    Ann Oncol; 2004 Oct; 15(10):1481-3. PubMed ID: 15367407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia.
    Treon SP; Hunter Z; Barnagan AR
    Clin Lymphoma; 2005 Mar; 5(4):273-7. PubMed ID: 15794864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab-based treatments in Waldenström's macroglobulinemia.
    Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia.
    Shaikh A; Habermann TM; Fidler ME; Kumar S; Leung N
    Clin Exp Nephrol; 2008 Aug; 12(4):292-295. PubMed ID: 18288560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment options in Waldenstrom's macroglobulinemia.
    Björkholm M
    Clin Lymphoma; 2004 Dec; 5(3):155-62. PubMed ID: 15636690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
    Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Case ∣ Hyperbicarbonatemia in a patient with Waldenstrom's macroglobulinemia. Pseudohyperbicarbonatemia due to paraproteinemia.
    Krish P; Jhaveri KD
    Kidney Int; 2012 Mar; 81(6):603-5. PubMed ID: 22373713
    [No Abstract]   [Full Text] [Related]  

  • 17. Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia.
    Treon SP; Hanzis C; Tripsas C; Ioakimidis L; Patterson CJ; Manning RJ; Sheehy P
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):133-5. PubMed ID: 21454214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The polyneuropathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab.
    Weide R; Heymanns J; Köppler H
    Br J Haematol; 2000 Jun; 109(4):838-41. PubMed ID: 10929038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An unusual reoccurrence of Waldenstrom's macroglobulinemia as pleural effusions that had a discordant response with treatment.
    Amin CJ; Rabinowitz I
    Clin Lab Haematol; 2005 Jun; 27(3):200-2. PubMed ID: 15938727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rituximab on a patient with Waldenström's macroglobulinaemia with deletion 13q14.
    Mori A; Tamaru J; Kondo H
    Eur J Haematol; 2002; 69(5-6):321-3. PubMed ID: 12460239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.